Related Experiment Videos
FPL 63012AR: a potent D1-receptor agonist
G W Smith1, J B Farmer, F Ince
1Fisons plc, Department of Pharmacology, Loughborough, Leicestershire.
British Journal of Pharmacology
|June 1, 1990
Summary
FPL 63012AR is a novel D1-receptor agonist, more potent than dopamine, that improves renal perfusion. It also inhibits noradrenaline uptake, offering potential clinical benefits for reducing afterload.
Area of Science:
- Pharmacology
- Neuropeptide Research
Background:
- Dopamine is a key neurotransmitter affecting renal function and vascular tone.
- Selective D1-receptor agonists are sought for therapeutic applications in cardiovascular and renal diseases.
Purpose of the Study:
- To characterize the pharmacological profile of FPL 63012AR.
- To evaluate its potential as a D1-receptor agonist and its effects on renal and vascular parameters.
Main Methods:
- In vitro receptor binding assays and functional assays.
- In vivo studies in anesthetized and conscious dogs and rabbits.
- Measurement of renal vascular resistance, blood flow, and blood pressure.
Main Results:
- FPL 63012AR demonstrated potent D1-receptor agonist activity in the dog kidney, reducing renal vascular resistance.
- It potently inhibited [3H]-noradrenaline uptake (Uptake1) in brain synaptosomes, exceeding dopamine's potency.
- Intravenous administration in dogs led to reduced vascular resistance, increased renal blood flow, hypotension, and tachycardia.
Conclusions:
- FPL 63012AR represents a novel class of potent D1-receptor agonists.
- Its ability to enhance renal perfusion and reduce afterload suggests potential clinical utility.